Now showing items 1-4 of 4

    • Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. 

      Baxter, JS; Leavy, OC; Dryden, NH; Maguire, S; Johnson, N; Fedele, V; Simigdala, N; Martin, L-A; Andrews, S; Wingett, SW; Assiotis, I; Fenwick, K; Chauhan, R; Rust, AG; Orr, N; Dudbridge, F; Haider, S; Fletcher, O (2018-03-12)
      Genome-wide association studies (GWAS) have identified approximately 100 breast cancer risk loci. Translating these findings into a greater understanding of the mechanisms that influence disease risk requires identification ...
    • Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. 

      Naidoo, K; Wai, PT; Maguire, SL; Daley, F; Haider, S; Kriplani, D; Campbell, J; Mirza, H; Grigoriadis, A; Tutt, A; Moseley, PM; Abdel-Fatah, TMA; Chan, SYT; Madhusudan, S; Rhaka, EA; Ellis, IO; Lord, CJ; Yuan, Y; Green, AR; Natrajan, R (2018-01)
      Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. ...
    • Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. 

      Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; Knudsen, E; Pettitt, SJ; Ryan, CJ; Lord, CJ (2018-06-18)
      Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating ...
    • SOX11 promotes invasive growth and ductal carcinoma in situ progression. 

      Oliemuller, E; Kogata, N; Bland, P; Kriplani, D; Daley, F; Haider, S; Shah, V; Sawyer, EJ; Howard, BA (2017-10)
      Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature mammary ...